Mid-career investigator award in allogeneic adoptive immunotherapy

同种异体过继免疫疗法职业中期研究员奖

• 批准号: 7458790
• 负责人: DAVID L PORTER
• 金额: $ 15.56万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7458790
• 关键词: Adoptive Immunotherapy; Allogenic; Applications Grants; Award; Basic Science; Cell Therapy; Clinic; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Commit; Data; Development; Education; Faculty; Fostering; Funding; Funding Opportunities; Future; Goals; Growth; Growth and Development function; Immunotherapy; Individual; Infusion procedures; Lead; Link; Malignant Neoplasms; Manuscripts; Mentors; Molecular Immunology; Numbers; Patient Care; Patients; Pre-Clinical Model; Preparation; Productivity; Program Development; Research; Research Design; Research Personnel; Resources; Scientist; Spiral Computed Tomography; Staging; Supervision; Thinking; Time; Training; Translating; Translational Research; Transplantation; Work; cancer immunotherapy; cancer therapy; career; design; improved; innovation; interest; next generation; novel; patient oriented research; pre-clinical research; programs; protocol development; symposium

DESCRIPTION (provided by applicant): Dr. Porter's major career focus has been on POR for cancer through innovative applications of cellular immunotherapy. This application describes both a research program in allogeneic cellular therapy, and a detailed proposal for mentoring junior investigators in POR. The research goals are to use important scientific discoveries and preclinical models to generate novel, effective and safe allogeneic cellular therapies to treat cancer. This application is to support dedicated time to enhance personal clinical and translational research, to mentor several exceptional junior clinical scientists in POR and career development, to integrate scientific collaborations with the innovative clinical research program, and to concentrate on personal career and program development. Each mentee will receive direct mentoring, support, and supervision; regular meetings will be set with each mentee and lab group, and monthly meetings will occur with the full program. A research clinic will be established to maximize research potential and mentoring opportunities. Dr. Porter will work with each mentee to insure successful participation in POR and will oversee pre-clinical research design, protocol development, patient care, data presentation and manuscript preparation. He will advise and assist them to identify funding opportunities and with preparation of grant applications. He will assist them with collaborations and networking vital for career development, building of regional and national reputations, and to foster independent thought and academic growth. Through this award, several projects will be completed, and others developed and initiated by the PI or a trainee. Each project is directly relevant to the treatment for cancer. The PI will have opportunity for additional intellectual pursuits through meetings, conferences, and expanded education relevant to cellular immunotherapy. These efforts will result in an infusion of ideas, energy, resources, and collaborations that will link the rapid advances in cellular and molecular immunology to clinical transplantation therapy and unite the group into a premier translational research program in adoptive immunotherapy. This will provide an ideal framework to train the next generation of leading clinical investigators, be vital for career development, expand our ability to rapidly translate novel therapies into clinical trials, lead quickly to additional independent funding, and rapidly advance the application of cellular immunotherapy for cancer.

描述（由申请人提供）：波特博士的主要职业重点是通过细胞免疫疗法的创新应用对癌症进行POR。该申请描述了同种异体细胞治疗的研究计划，以及在POR中指导初级研究人员的详细建议。研究目标是利用重要的科学发现和临床前模型来产生新型、有效且安全的同种异体细胞疗法来治疗癌症。该应用程序是为了支持专门的时间来加强个人临床和转化研究，在POR和职业发展中指导几位杰出的初级临床科学家，将科学合作与创新的临床研究计划相结合，并专注于个人职业和计划发展。每个学员将获得直接的指导，支持和监督;定期会议将与每个学员和实验室小组，每月会议将与整个计划发生。将建立一个研究诊所，以最大限度地发挥研究潜力和提供指导机会。Porter博士将与每位学员合作，以确保成功参与POR，并将监督临床前研究设计，方案制定，患者护理，数据展示和手稿准备。他将建议和协助他们寻找资助机会，并准备赠款申请。他将协助他们与合作和网络至关重要的职业发展，区域和国家声誉的建设，并促进独立思考和学术成长。通过该奖项，将完成几个项目，其他项目将由PI或实习生开发和发起。每个项目都与癌症的治疗直接相关。PI将有机会通过会议，会议和与细胞免疫治疗相关的扩展教育进行额外的智力追求。这些努力将导致思想，能量，资源和合作的注入，将细胞和分子免疫学的快速发展与临床移植治疗联系起来，并将该小组团结成过继免疫治疗的首要转化研究计划。这将为培养下一代领先的临床研究人员提供一个理想的框架，对职业发展至关重要，扩大我们快速将新疗法转化为临床试验的能力，迅速获得额外的独立资金，并迅速推进细胞免疫疗法在癌症中的应用。